{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:51:52Z","timestamp":1792007512395,"version":"4.4.0"},"reference-count":57,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: We conducted a comprehensive investigation to explore the pathological expression of the CXCR4 receptor in lymphoproliferative disorders (LPDs) using [68Ga]Ga-Pentixafor PET\/CT or PET\/MRI technology. The PICO question was as follows: What is the diagnostic role (outcome) of [68Ga]Ga-Pentixafor PET (intervention) in patients with LPDs (problem\/population)? Methods: The study was written based on the reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines, and it was registered on the prospective register of systematic reviews (PROSPERO) website (CRD42024506866). A comprehensive computer literature search of Scopus, MEDLINE, Scholar, and Embase databases was conducted, including articles indexed up to February 2024. To the methodological evaluation of the studies used the quality assessment of diagnosis accuracy studies-2 (QUADAS-2) tool. Results: Of the 8380 records discovered, 23 were suitable for systematic review. Fifteen studies (on 571 LPD patients) focused on diagnosis and staging, and eight trials (194 LPD patients) assessed treatment response. Conclusions: The main conclusions that can be inferred from the published studies are as follows: (a) [68Ga]Ga-Pentixafor PET may have excellent diagnostic performance in the study of several LPDs; (b) [68Ga]Ga-Pentixafor PET may be superior to [18F]FDG or complementary in some LPDs variants and settings; (c) multiple myeloma seems to have a high uptake of [68Ga]Ga-Pentixafor. Overall, this technique is probably suitable for imaging, staging, and follow-up on patients with LPD. Due to limited data, further studies are warranted to confirm the promising role of [68Ga]Ga-Pantixafor in this context.<\/jats:p>","DOI":"10.3390\/jcm13102945","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:26:17Z","timestamp":1715858777000},"page":"2945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Clinical Role of CXCR4-Targeted PET on Lymphoproliferative Disorders: A Systematic Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1716-0660","authenticated-orcid":false,"given":"Maryam","family":"Zamanian","sequence":"first","affiliation":[{"name":"Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, ASST Spedali Civili Brescia, 25128 Brescia, Italy"},{"name":"Nuclear Medicine Department, University of Brescia, 25121 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-780X","authenticated-orcid":false,"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana, 6900 Lugano, Switzerland"},{"name":"Division of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland"},{"name":"Faculty of Biology and Medicine, University of Lausanne, 1015 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5438-8230","authenticated-orcid":false,"given":"Alessio","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraj","family":"Abedi","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.hoc.2018.08.003","article-title":"A Review of Primary Cutaneous CD30+ Lymphoproliferative Disorders","volume":"33","author":"Chen","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_2","unstructured":"Justiz Vaillant, A.A., and Stang, C.M. (2024). Lymphoproliferative Disorders, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0950-3536(05)80175-1","article-title":"Chronic lymphoproliferative disorders: Classification and diagnosis","volume":"6","author":"Litz","year":"1993","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_4","unstructured":"Moticka, E.J. (2016). A Historical Perspective on Evidence-Based Immunology, Elsevier."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5858\/arpa.2018-0190-RS","article-title":"Autoimmune Lymphoproliferative Syndrome: An Overview","volume":"144","author":"Matson","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fped.2018.00334","article-title":"Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders","volume":"6","author":"Sawada","year":"2018","journal-title":"Front. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2006-01-010124","article-title":"Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)","volume":"6","author":"Teachey","year":"2006","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13014-018-1146-3","article-title":"Auto- versus human-driven plan in mediastinal Hodgkin lymphoma radiation treatment","volume":"13","author":"Clemente","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-018-0748-0","article-title":"Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?","volume":"20","author":"Freeman","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1182\/blood-2010-04-280347","article-title":"Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop","volume":"116","author":"Oliveira","year":"2010","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00261-016-0873-x","article-title":"Role of multimodality imaging in the diagnosis of lymphoproliferative malignancies and hematologic disorders of the kidneys","volume":"42","author":"Karaosmanoglu","year":"2017","journal-title":"Abdom. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"Homey","year":"2001","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ni.f.214","article-title":"Chemokines and leukocyte traffic","volume":"9","author":"Sallusto","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2003.10.003","article-title":"The significance of cancer cell expression of the chemokine receptor CXCR4","volume":"14","author":"Balkwill","year":"2003","journal-title":"Semin. Cancer Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_17","first-page":"1347","article-title":"Emerging targets in cancer management: Role of the CXCL12\/CXCR4 axis","volume":"6","author":"Cojoc","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tang, Y., Gu, Z., Fu, Y., and Wang, J. (2019). CXCR3 from chemokine receptor family correlates with immune infiltration and predicts poor survival in osteosarcoma. Biosci. Rep., 39.","DOI":"10.1042\/BSR20192134"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1152\/physrev.00049.2010","article-title":"A molecular imaging primer: Modalities, imaging agents, and applications","volume":"92","author":"James","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.bmc.2013.12.012","article-title":"Preclinical evaluation of a CXCR4-specific 68Ga-labelled TN14003 derivative for cancer PET imaging","volume":"22","author":"George","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s11307-013-0640-0","article-title":"Comparison of 18F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression","volume":"15","author":"Zhang","year":"2013","journal-title":"Mol. Imaging Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7150\/thno\/v01p0251","article-title":"PET imaging of CXCR4 using copper-64 labeled peptide antagonist","volume":"1","author":"Jacobson","year":"2011","journal-title":"Theranostics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.nucmedbio.2006.01.006","article-title":"Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors","volume":"33","author":"Hanaoka","year":"2006","journal-title":"Nucl. Med. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","article-title":"PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent","volume":"52","author":"Gourni","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET imaging of CXCR4 receptors in cancer by a new optimised ligand","volume":"6","author":"Demmer","year":"2011","journal-title":"Chem. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20211272","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET\/CT: Comparison with 18F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11307-021-01664-3","article-title":"CXCR4-Directed PET\/CT with [68Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [18F]FDG PET\/CT","volume":"24","author":"Chen","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2967\/jnumed.123.266074","article-title":"Chemokine Receptor PET\/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma","volume":"64","author":"Duell","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood.2021013239","article-title":"CXCR4 PET\/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication","volume":"139","author":"Mayerhoefer","year":"2022","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","article-title":"Prognostic significance of 68Ga-Pentixafor PET\/CT in multiple myeloma recurrence: A comparison to 18F-FDG PET\/CT and laboratory results","volume":"35","author":"Kuyumcu","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.119.226134","article-title":"68Ga-Pentixafor PET\/CT for Imaging of Chemokine Receptor 4 Expression in Waldenstr\u00f6m Macroglobulinemia\/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET\/CT","volume":"60","author":"Luo","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/RLU.0000000000004638","article-title":"68Ga-Pentixafor PET\/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI","volume":"48","author":"Mayerhoefer","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s11307-023-01830-9","article-title":"Comparison of FDG-PET\/CT and bone scintigraphy for detection of bone metastases in breast cancer","volume":"25","author":"Kosmala","year":"2023","journal-title":"Mol. Imaging Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.7150\/thno.75847","article-title":"Reduced splenic uptake on 68Ga-Pentixafor-PET\/CT imaging in multiple myeloma\u2014A potential imaging biomarker for disease prognosis","volume":"12","author":"Kraus","year":"2022","journal-title":"Theranostics"},{"key":"ref_36","first-page":"1687","article-title":"A Imaging of CXC motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40336-021-00458-5","article-title":"[68Ga]-Pentixafor PET\/CT imaging of lymphoproliferative malignancies","volume":"9","author":"Kuyumcu","year":"2021","journal-title":"Clin. Transl. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7150\/thno.48620","article-title":"CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: Comparison with [18F]FDG-PET","volume":"11","author":"Mayerhoefer","year":"2021","journal-title":"Theranostics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/RLU.0000000000003404","article-title":"Assessment of central nervous system lymphoma based on CXCR4 expression in vivo using [68Ga] Pentixafor-PET\/MRI","volume":"46","author":"Berghoff","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13550-021-00852-0","article-title":"Semiquantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET\/CT in response assessment of Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma","volume":"11","author":"Pan","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/RLU.0000000000003760","article-title":"Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET\/CT in Response Assessment of Waldenstr\u00f6m Macroglobulinemia\/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET\/CT","volume":"46","author":"Pan","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","article-title":"Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET\/CT","volume":"62","author":"Duell","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zhou, X., Dierks, A., Kertels, O., Kircher, M., Schirbel, A., Samnick, S., Buck, A.K., Knorz, S., B\u00f6ckle, D., and Scheller, L. (2020). 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET\/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. Cancers, 12.","DOI":"10.3390\/cancers12082333"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2967\/jnumed.120.241703","article-title":"CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma","volume":"61","author":"Herhaus","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_45","first-page":"984","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"8","author":"Jager","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_46","first-page":"210","article-title":"Evaluation of chemokine receptor-4 expression by 68Ga\u2013Pentixafor pet\/ct in patients with multiple myeloma","volume":"33","author":"Ozkan","year":"2020","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.7150\/thno.31032","article-title":"Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET\/MRI","volume":"9","author":"Haug","year":"2019","journal-title":"Theranostics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: Comparison to 18F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/RLI.0000000000000469","article-title":"A Fully Automatic Approach for Multimodal PET and MR Image Segmentation in Gamma Knife Treatment Planning","volume":"53","author":"Mayerhoefer","year":"2018","journal-title":"Investig. Radiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma\u2014Comparison to [18F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma","volume":"7","author":"Herrmann","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11912-009-0019-1","article-title":"The chemokine receptors CXCR4 and CXCR3 in cancer","volume":"11","author":"Fulton","year":"2009","journal-title":"Curr. Oncol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.radonc.2016.12.033","article-title":"Challenges and opportunities in primary CNS lymphoma: A systematic review","volume":"122","author":"Kerbauy","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"(2011). What is an MRI scan and what can it do?. Drug Ther. Bull., 49, 141\u2013144.","DOI":"10.1136\/dtb.2011.02.0073"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s002590050487","article-title":"The chemokine receptors CXCR4 and CXCR3 in cancer","volume":"26","author":"Hustinx","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00117-019-0524-7","article-title":"Contrast agent-free breast MRI: Advantages and potential disadvantages","volume":"59","author":"Baltzer","year":"2019","journal-title":"Der Radiol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Albano, D., Dondi, F., Bertagna, F., and Treglia, G. (2022). The role of [68Ga] Ga-Pentixafor PET\/CT or PET\/MRI in lymphoma: A systematic review. Cancers, 14.","DOI":"10.3390\/cancers14153814"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/10\/2945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:35Z","timestamp":1760107415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/10\/2945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jcm13102945"],"URL":"https:\/\/doi.org\/10.3390\/jcm13102945","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}